ATAI Life Sciences Inc.

NASADAQ: ATAI

Company Overview

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The company was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape.

atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

The company's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.

atai is headquartered in Berlin, with offices in New York.

Financial Highlights

$20,146,000

Revenue (ttm)

$0

Gross Profit (ttm)

-$3.94

Diluted EPS (ttm)

Management Team

Mr. Florian Brand
Co-Founder, MD & CEO

Dr. Srinivas G. Rao M.D., Ph.D.
Co-Founder & Chief Scientific Officer

Mr. Gregory L. Weaver CPA, M.B.A.
MD & CFO

Mr. Christian Angermayer
Founder & Chairman of the Supervisory Board

Mr. Lars Christian Wilde
Co-Founder

Mr. Roman Dahl
VP of Operations & Innovation

Ms. Madison Crawford
Sr. Mang. of Accounting

Mr. Colin Keeler
Mang. of Corp. Fin.

Mr. Ryan Barrett
VP of Corp. Devel. & Gen. Counsel

Ms. Camilla Dormer
VP of Communications

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$0

Shares Outstanding
0

Shares Short (% of Float)
()

Insider Ownership
9%